Skip to content
NYSE · DENTAL EQUIPMENT & SUPPLIES · LARGE CAP

Envista Holdings Corp. NVST

9 fiscal years on record · USD · FY2025 reported · SEC filings only
$2.7B
▲ 8.3% YoY
$47.0M
$230.4M
▼ 23.9% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

It serves dental professionals in over 130 countries through its commercial organization and distribution partners. As of December 31, 2025, it employed approximately 12,000 persons, of whom approximately 3,000 were employed in the U.S. and approximately 9,000 were employed outside of the U.S. Henry Schein, Inc. accounted for approximately 12% of its sales for 2025. Envista's business is operated through two segments: Specialty Products & Technologies, comprising its Dental Implant Solutions and Orthodontic Solutions businesses, and Equipment & Consumables, comprising its Diagnostic and Consumables Solutions businesses. Its Specialty Products & Technologies segment develops, manufactures and markets dental implant systems, including regenerative solutions, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, lab products, and loupes. Its Equipment & Consumables segment develops, manufactures, and markets dental equipment and supplies used in dental offices, including digital imaging systems, software, and other visualization and magnification systems, endodontic systems and related products, restorative materials and instruments, and infection prevention products. Envista was formed in 2018 as a wholly-owned subsidiary of Danaher Corporation.

Written from the business description in Envista Holdings Corp's annual report to the U.S. Securities and Exchange Commission, filed 12 February 2026. Every sentence was checked against that document before publication.

Growth

USD 2.7B
Revenue, FY2025 · full 9-year series below
Revenue $B Net income $B
FY2025 · Revenue 2.7 · Net income 0.0
1.0B2.0B-0.5B-1.0B
2017202020232025
Compound annual growth
+1.9%
+7.1%
−42.2%
+7.1%
−41.1%
+7.0%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +7.1% a year over the five years to FY2025 — but profit grew faster: net income at +7.1%, earnings per share at +7.0%.

The share count rose from 0.16B to 0.16B over the period.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

2 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 7.9% · Net 1.7%
5%10%-20%-40%
201720212025
ROE
FY2025 · ROE 1.6%
5%-10%-20%-30%
201720212025
Three returns, three denominators.

Each USD of equity produced 2 cents of profit this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 230.4
150M300M
201720212025

Total assetsUSD 5.7B
EquityUSD 3.1B
CashUSD 1.2B
Gross debtUSD 1.4B
Net debtUSD 236.6M
Current ratio2.38×

Net debt stands at 8% of equity.

The 9-year record

9 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
NVST, 9-year financial record
Metric 202520242023202220212020201920182017
Revenue $B2.72.52.62.62.51.92.32.82.8
Operating income $B0.2−1.00.00.30.30.00.20.30.4
EBITDA $B0.3−0.90.20.50.40.20.40.40.5
Income tax $B0.10.00.00.0−0.0−0.10.00.10.1
Net income $B0.0−1.1−0.10.20.30.00.20.20.3
Free cash flow $B0.20.30.20.10.30.20.30.30.3
EPS, diluted $0.28−6.50−0.601.371.920.201.601.802.35
Dividend / sh $◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————
ROE %1.6−31.5−2.45.98.80.95.24.8◌
Shares out B0.160.170.170.160.160.160.160.00◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 43 reconciliationsAUDITED

Reconciled in 9 of the 9 fiscal years we could check. 20 checks were skipped: the balance sheet is not tagged before 2017. 10 checks were skipped: EPS is not tagged before 2017. 10 checks were skipped: revenue is not tagged before 2017.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityDental Equipment & Supplies
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2017

Share this section

Download image